Eton Pharmaceuticals (ETON) Retained Earnings (2017 - 2025)
Eton Pharmaceuticals' Retained Earnings history spans 8 years, with the latest figure at -$112.5 million for Q4 2025.
- On a quarterly basis, Retained Earnings fell 4.26% to -$112.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$112.5 million, a 4.26% decrease, with the full-year FY2025 number at -$112.5 million, down 4.26% from a year prior.
- Retained Earnings hit -$112.5 million in Q4 2025 for Eton Pharmaceuticals, up from -$114.0 million in the prior quarter.
- Over the last five years, Retained Earnings for ETON hit a ceiling of -$87.0 million in Q1 2021 and a floor of -$114.0 million in Q3 2025.
- Historically, Retained Earnings has averaged -$103.1 million across 5 years, with a median of -$104.1 million in 2022.
- Biggest five-year swings in Retained Earnings: dropped 18.85% in 2021 and later increased 2.15% in 2023.
- Tracing ETON's Retained Earnings over 5 years: stood at -$94.1 million in 2021, then decreased by 9.59% to -$103.1 million in 2022, then fell by 0.91% to -$104.1 million in 2023, then fell by 3.67% to -$107.9 million in 2024, then decreased by 4.26% to -$112.5 million in 2025.
- Business Quant data shows Retained Earnings for ETON at -$112.5 million in Q4 2025, -$114.0 million in Q3 2025, and -$112.0 million in Q2 2025.